CRIMINI, EDOARDO

CRIMINI, EDOARDO  

Universita' degli Studi di MILANO  

Mostra records
Risultati 1 - 20 di 21 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 2023 Tarantino, PaoloAntonarelli, GabrieleBoscolo Bielo, LucaCrimini, EdoardoGiugliano, FedericaZagami, PaolaCorti, ChiaraTrapani, DarioCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go? 2023 Trapani, DarioCrimini, EdoardoCurigliano, Giuseppe + Book Part (author) -
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running? 2023 Trillo Aliaga, PamelaCorti, ChiaraCrimini, Edoardo + Article (author) -
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 2022 Tarantino, PaoloAntonarelli, GabrieleBoscolo Bielo, LucaMarra, AntonioCrimini, EdoardoGiugliano, FedericaZagami, PaolaCorti, ChiaraTrapani, DarioMorganti, StefaniaCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population 2022 Mazzarella LCrimini EUliano JCorti CTrillo Aliaga PRepetto MAntonarelli GCriscitiello CCurigliano G. + Article (author) -
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 2022 Mazzarella, LGiugliano, FNicolo', ECrimini, EUliano, JCorti, CRepetto, MAntonarelli, GAscione, LVivanet, GCriscitiello, CCurigliano, G + Article (author) -
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? 2022 Morganti S.Crimini E.Zagami P.Curigliano G. + Article (author) -
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 2022 Venetis K.Crimini E.Sajjadi E.Corti C.Guerini-Rocco E.Viale G.Curigliano G.Criscitiello C.Fusco N. Article (author) -
Characterization of low HER2 expressions in de-novo metastatic breast cancer 2021 Tarantino, PZagami, PGiugliano, FCrimini, ECorti, CUliano, JMorganti, SCriscitiello, CCurigliano, G + Article (author) -
Clinical development and current role of margetuximab for the treatment of breast cancer 2021 Uliano J.Morganti S.Giugliano F.Crimini E.Curigliano G. + Article (author) -
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 2021 Crimini E.Corti C.Repetto M.Giugliano F.Antonarelli G.Zagami P.Morganti S.Uliano J.Curigliano G. + Article (author) -
Margetuximab for the treatment of HER2-positive metastatic breast cancer 2021 Morganti S.Uliano J.Giugliano F.Crimini E.Curigliano G. + Article (author) -
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy 2021 Giugliano, FCrimini, EUliano, JCorti, CRepetto, MAntonarelli, GVivanet, GCriscitiello, CCurigliano, G + Article (author) -
COVID-19 related risk in patients enrolled in early-phase clinical trials 2021 Morganti, SCorti, CVivanet, GCrimini, EAntonarelli, GCurigliano, G + Article (author) -
SARS-CoV-2 vaccines for cancer patients: a call to action 2021 Corti, ChiaraCrimini, EdoardoPravettoni, GabriellaCurigliano, Giuseppe + Article (author) -
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 2021 Trillo Aliaga P.Trapani D.Crimini E.Antonarelli G.Vivanet G.Morganti S.Corti C.Criscitiello C.Curigliano G. + Article (author) -
First line treatment of BRAF mutated advanced melanoma: Does one size fit all? 2021 Giugliano, FedericaCrimini, EdoardoZagami, PaolaUliano, JacopoCorti, ChiaraTrapani, DarioCurigliano, Giuseppe + Article (author) -
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis 2021 Trapani, DCorti, CCrimini, EBellerba, FCriscitiello, CCurigliano, G + Article (author) -
Precision medicine in breast cancer : From clinical trials to clinical practice 2021 Crimini, EdoardoRepetto, MatteoCurigliano, Giuseppe + Article (author) -
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 2021 Repetto M.Crimini E.Giugliano F.Morganti S.Curigliano G. + Article (author) -